Scientists at BellBrook Labs developed a new monoclonal antibody for AMP and used it to enhance the sensitivity of the company’s Transcreener AMP²/GMP² Assay, a fluorescent high throughput screening assay that can be used for hundreds of enzymes, among them targets for cancer, cardiovascular diseases, and infectious diseases. The increased sensitivity will reduce enzyme costs by as much as two- to four-fold for phosphodiesterase assays, ligase assays, and related assays, which could have a significant impact on high throughput screening decisions in the current cost-conscious drug discovery environment.
Madison, WI (PRWEB) April 21, 2012 — BellBrook Labs announced the launch of an improved Transcreener AMP²/GMP² Assay that uses a new monoclonal antibody, allowing more sensitive detection of hundreds of enzymes of potential therapeutic interest including ligases, synthetases, phosphodiesterases and sialyltransferases. These and related enzymes are being targeted for a diverse range of diseases, including cancer, cardiovascular disease, and infectious diseases, and robust high throughput assays are critical for these efforts. As with the first generation assay, the new Transcreener AMP²/GMP² Assay relies on a highly specific antibody that recognizes AMP, GMP and CMP, but not the cyclic or triphosphate forms of these nucleotides.